{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Response rates were classified according to the International Uniform Response Criteria for Multiple Myeloma (Durie et al, 2006). Complete Response (CR): negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas , and ≤ 5% plasma cells in the bone marrow. Stringent CR (sCR): CR as defined above, and normal free light chain (FLC) ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence, based on a κ/λ ratio of \\> 4:1 or \\< 1:2 performed on a minimum of 100 plasma cells.","groups":[{"description":"Intravenous (IV) infusions of natalizumab 300 mg once every 28 days for 6 months.","id":"OG000","title":"Natalizumab 300 mg"},{"description":"Intravenous (IV) infusions of natalizumab 450 mg once every 28 days for 6 months.","id":"OG001","title":"Natalizumab 450 mg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Day 1 up to Month 6","title":"Number Of Participants Who Achieve A Complete Response","type":"SECONDARY","unitOfMeasure":"participants"}